Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience.

ABSTRACT:

Background

Although atezolizumab plus bevacizumab (Atez/bev) treatment has been developed for unresectable hepatocellular carcinoma (u-HCC), changes in hepatic function during therapy have yet to be reported.

Aim

This retrospective clinical study aimed to elucidate early responses to Atez/Bev.

Methods

From September 2020 to April 2021, 171 u-HCC patients undergoing Atez/Bev treatment were enrolled (BCLC stage A:B:C:D = 5:68:96:2). Of those, 75 had no prior history of systemic treatment. Relative changes in hepatic function and therapeutic response were assessed using albumin-bilirubin (ALBI) score and Response Evaluation Criteria in Solid Tumors (RECIST), ver. 1.1, respectively.

Results

In initial imaging examination findings, objective response rates for early

SUBMITTER: Hiraoka A 

PROVIDER: S-EPMC8842687 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature